title: Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?
abstract: While neuromyelitis optica (NMO) immunoglobulin (Ig) G is considered the hallmark serologic marker of NMO, its association is not absolute, as NMO IgG is not detected in approximately one-fourth of the patients diagnosed with NMO spectrum disorder (NMOSD). Thus, the recent discovery that antibodies to myelin oligodendrocyte glycoprotein (MOG) are detected in some NMO IgG-seronegative patients manifesting clinical and neuroimaging signs of NMO or NMOSD has created tremendous excitement. However, it may be premature to classify this subgroup as NMOSD. NMO is considered an autoimmune astrocytopathy, and aquaporin-4 (AQP4), expressed on astrocytes, is recognized as the target autoantigen of NMO IgG. As its name denotes, MOG is produced by oligodendrocytes, CNS myelin-producing cells, and MOG is well-recognized as one of the candidate autoantigens in multiple sclerosis (MS) and acute disseminated encephalomyelitis (ADEM). Thus, is it possible that the clinical NMOSD-like phenotype associated with MOG-specific antibodies represents a variant of opticospinal MS or ADEM but not AQP4 autoimmunity or NMOSD? Whether this MOG-Ig positive AQP4-seronegative phenotype should be classified as NMOSD, opticospinal MS, or a unique entity is not simply a theoretical question but rather has practical implications for patients, their physicians, insurance carriers, and clinical investigators conducting NMO treatment trials.
authors: Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco; and Abbvie Bioresearch Center Inc. (A.J.S.), Worcester, MA.
authors: Scott S
authors: SS
authors: Zamvil
authors: Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco; and Abbvie Bioresearch Center Inc. (A.J.S.), Worcester, MA.
authors: Anthony J
authors: AJ
authors: Slavin
references: Nat Med. 2008 Mar;14(3):337-42
references: 18278054
references: Nat Med. 2007 Feb;13(2):211-7
references: 17237795
references: J Clin Invest. 2006 Sep;116(9):2385-92
references: 16955140
references: J Neurol Sci. 2014 Apr 15;339(1-2):223-5
references: 24576801
references: Ann Neurol. 2000 Jun;47(6):707-17
references: 10852536
references: Brain Pathol. 2014 Jan;24(1):83-97
references: 24345222
references: Am J Pathol. 1988 Mar;130(3):443-54
references: 2450462
references: J Clin Invest. 2006 Sep;116(9):2393-402
references: 16955141
references: Neurology. 2006 May 23;66(10 ):1485-9
references: 16717206
references: JAMA Neurol. 2014 Mar;71(3):276-83
references: 24425068
references: Nat Rev Neurol. 2010 Jul;6(7):383-92
references: 20639914
references: Ann Neurol. 2009 Dec;66(6):833-42
references: 20033986
references: Ann Neurol. 2011 Feb;69(2):292-302
references: 21387374
references: J Exp Med. 2008 Jul 7;205(7):1535-41
references: 18573909
references: Ann Neurol. 2012 Jul;72(1):53-64
references: 22807325
references: Mult Scler. 2013 Jul;19(8):1052-9
references: 23257621
references: Ann Neurol. 2009 Nov;66(5):630-43
references: 19937948
references: Mult Scler. 2015 Jun;21(7):866-74
references: 25344373
references: Neurology. 2012 Aug 28;79(9):945-6
references: 22895587
references: Mult Scler. 2015 Apr;21(5):656-9
references: 25257613
references: Neurology. 2012 Sep 18;79(12):1273-7
references: 22914827
references: Nat Med. 1999 Feb;5(2):170-5
references: 9930864
references: J Neurol Neurosurg Psychiatry. 2015 Mar;86(3):265-72
references: 25121570
references: Neurology. 2011 Aug 9;77(6):580-8
references: 21795651
references: Mult Scler. 2012 Apr;18(4):398-408
references: 22343184
references: Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e20
references: 25340072
references: J Neurol Sci. 2011 Jul 15;306(1-2):82-90
references: 21550068
references: Neurol Neuroimmunol Neuroinflamm. 2014 May 22;1(1):e12
references: 25340056
references: Mult Scler. 2013 Jun;19(7):941-6
references: 23128668
references: J Neuroimmunol. 2002 Oct;131(1-2):201-7
references: 12458053
references: J Immunol. 2009 Sep 15;183(6):4067-76
references: 19687098
references: J Exp Med. 2013 Dec 16;210(13):2921-37
references: 24323356
references: Neurology. 2010 Jul 20;75(3):208-16
references: 20644148
references: Neurol Neuroimmunol Neuroinflamm. 2014 Aug 14;1(2):e22
references: 25340074
references: J Neuroinflammation. 2011 Dec 28;8:184
references: 22204662
references: Clin Immunol. 2011 Mar;138(3):247-54
references: 21169067
references: Neurology. 2014 Feb 11;82(6):474-81
references: 24415568
references: J Exp Med. 1998 Jul 6;188(1):169-80
references: 9653093
references: J Exp Med. 2003 May 5;197(9):1073-81
references: 12732654
references: J Clin Invest. 2001 Oct;108(8):1133-9
references: 11602620
references: Arch Neurol. 2010 Aug;67(8):1016-7
references: 20697055
references: J Neurol. 2008 Feb;255(2):305-7
references: 18004636
references: Ann Neurol. 2012 Mar;71(3):323-33
references: 22374891
references: Lancet. 2004 Dec 11-17;364(9451):2106-12
references: 15589308
references: Mult Scler. 2012 Jan;18(1):108-12
references: 21868485
references: Mult Scler. 2010 Jan;16(1):21-9
references: 19995845
references: Arch Neurol. 2008 Jan;65(1):78-83
references: 18195142
references: Ann Neurol. 2009 Nov;66(5):617-29
references: 19938104
references: Annu Rev Immunol. 2011;29:621-63
references: 21314428
references: Acta Neuropathol Commun. 2014 Mar 31;2:35
references: 24685353
references: Brain Pathol. 2007 Apr;17(2):210-8
references: 17388952
references: J Neuroinflammation. 2010 Sep 08;7:52
references: 20825655